Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?

被引：6
|
作者：
Remon, Jordi [1 ]
Hendriks, Lizza [2 ]
Aspeslagh, Sandrine [3 ]
Besse, Benjamin [4 ,5 ]
机构：
[1] HM Delfos, Ctr Integral Oncol Clara Campal Barcelona, Med Oncol Dept, Barcelona, Spain
[2] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Pulm Dis Dept, Maastricht, Netherlands
[3] UZ Brussels VUB, Dept Med Oncol, Brussels, Belgium
[4] Gustave Roussy, Dept Canc Med, Villejuif, France
[5] Univ Paris Saclay, Orsay, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
LUNG-CANCER; EFFICACY; SAFETY;
D O I：
10.1016/j.jtho.2019.07.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1701 / 1703
页数：3
相关论文
共 50 条
  • [31] An overview of immune checkpoint therapy in autoimmune diseases
    Mohammadi, Pantea
    Hesari, Mahvash
    Chalabi, Maryam
    Salari, Farhad
    Khademi, Fatemeh
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 107
  • [32] Use of Immune Checkpoint Inhibitors in the Treatment of Patients with Cancer and Preexisting Autoimmune Diseases: A Systematic Review of Case Reports
    Abdel-Wahab, Noha
    Shah, Mohsin
    Suarez-Almazor, Maria
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [33] Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies
    Xie, Wenhui
    Huang, Hong
    Xiao, Shiyu
    Fan, Yong
    Deng, Xuerong
    Zhang, Zhuoli
    AUTOIMMUNITY REVIEWS, 2020, 19 (12)
  • [34] SAFETY AND EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH CANCER AND PREEXISTING AUTOIMMUNE DISEASES: A NATIONWIDE MULTICENTER RETROSPECTIVE STUDY
    Tison, A.
    Quere, G.
    Misery, L.
    Funck-Brentano, E.
    Danlos, F. -X.
    Bonniaud, B.
    Scalbert, C.
    Lesimple, T.
    Martinez, S.
    Marcq, M.
    Chouaid, C.
    Dubos, C.
    Brunet-Possenti, F.
    Stavris, C.
    Chiche, L. Y.
    Cornec, D.
    Kostine, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 147 - 147
  • [35] Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Liu, Xin
    Li, Su
    Ke, Liyuan
    Cui, Hongxia
    BMC CANCER, 2024, 24 (01)
  • [36] Outcomes in NSCLC Patients with Early Termination of Immune Checkpoint Inhibitors Due to Toxicities
    Davies, A.
    Menon, S.
    Alamgeer, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S245 - S245
  • [37] Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors
    Krizova, Ludmila
    Benesova, Iva
    Zemanova, Petra
    Spacek, Jan
    Strizova, Zuzana
    Humlova, Zuzana
    Mikulova, Veronika
    Petruzelka, Lubos
    Vocka, Michal
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (02)
  • [38] Retrospective analysis for stool abnormality on the efficacy of immune checkpoint inhibitors in patients with NSCLC
    Chihara, Yusuke
    Yamada, Tadaaki
    Takayama, Koichi
    CANCER SCIENCE, 2018, 109 : 1428 - 1428
  • [39] Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors
    Ludmila Krizova
    Iva Benesova
    Petra Zemanova
    Jan Spacek
    Zuzana Strizova
    Zuzana Humlova
    Veronika Mikulova
    Lubos Petruzelka
    Michal Vocka
    Journal of Cancer Research and Clinical Oncology, 150
  • [40] Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
    Miyawaki, Taichi
    Naito, Tateaki
    Kodama, Akihro
    Nishioka, Naoya
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Murakami, Haruyasu
    Notsu, Akifumi
    Mori, Keita
    Harada, Hideyuki
    Endo, Masahiro
    Takahashi, Kazuhisa
    Takahashi, Toshiaki
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (02):
12345